Nautilus Biotechnology, Inc.
NAUT- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001808805
No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Nautilus Biotechnology, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 72 | 81 | +9 |
| Shares | 41.0M | 59.6M | +18.6M (+45.4%) |
| Value | $245.1M | $234.8M | −$10.3M (−4.2%) |
New holders (22)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (13)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Federated Hermes, Inc. | 800,000 | $4.91M |
| Boxer Capital, LLC | 750,000 | $4.61M |
| Avidity Partners Management LP | 600,000 | $3.68M |
| Suvretta Capital Management, LLC | 314,835 | $1.93M |
| Casdin Capital, LLC | 225,000 | $1.38M |
| Occudo Quantitative Strategies LP | 85,148 | $523.0K |
| Belvedere Trading LLC | 52,539 | $292.0K |
| Capstone Investment Advisors, LLC | 20,672 | $127.0K |
| Group One Trading, L.P. | 20,252 | $124.0K |
| Raymond James & Associates | 18,797 | $115.0K |
| ExodusPoint Capital Management, LP | 13,438 | $83.0K |
| Red Tortoise LLC | 600 | $1.00K |
| Cutler Group LP | 131 | $0 |